Related Experiment Videos
Lentivectors for regulated and reversible cutaneous gene delivery
Zurab Siprashvili1, Paul A Khavari
1VA Alto Healthcare System, Palo Alto, California 94025, USA.
Summary
This study developed a novel gene therapy for anemia using lentivectors in human skin. Topical steroids control erythropoietin (Epo) levels, offering a regulated, long-term protein expression method.
Area of Science:
- Biotechnology
- Gene Therapy
- Dermatology
Background:
- Systemic therapeutic proteins are valuable but face challenges with recombinant protein cost and gene delivery inefficiency.
- The skin offers potential for sustained, topically regulated protein expression after gene delivery.
Purpose of the Study:
- To develop a gene delivery system for regulated therapeutic protein expression in skin.
- To establish a method for topical control of protein levels and gene expression persistence.
Main Methods:
- Generated lentivectors for regulated gene delivery and persistence in skin.
- Administered lentivectors into human skin grafts on immunodeficient mice.
- Utilized topical glucocorticoid ligands to control gene expression and protein levels.
- Employed a 4-hydroxytamoxifen-inducible Cre recombinase for proviral excision and gene delivery abrogation.
Main Results:
- Topical glucocorticoids successfully regulated erythropoietin (Epo) levels and hematocrit in vivo.
- Gene delivery was effectively abrogated by glucocorticoid cessation and proviral excision.
- Demonstrated durable, topically controlled systemic protein delivery from human skin.
Conclusions:
- Developed a novel approach for sustained, topically regulated therapeutic protein production in skin.
- This method offers a potential alternative to repeated injections and inefficient gene delivery systems.
- Highlights the potential of skin as a bioreactor for controlled systemic protein therapy.